Discover How Sefia™ Expansion System Can Be Used With Various Cell Culture Media For Manufacture Of CAR T Cells

CAR T cell therapies have transformed treatment options for hematologic malignancies, but their evolving complexity is reshaping expectations for manufacturing. Advances in engineering and culture strategies are driving greater focus on expanding T memory stem cell populations, pushing processes toward higher precision and consistency. As a result, equipment flexibility has become essential—particularly the ability to support activation, transduction, and expansion across varying media conditions. At the same time, a steady shift toward serum-free media reflects growing demands for reproducibility, regulatory alignment, and tighter process control. Together, these trends highlight a critical need for adaptable, future-ready manufacturing approaches that can keep pace with innovation in cell therapy design and scale.
Discover how these shifts are influencing next-generation process strategies.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.